Free Newsletter
Pfizer R&D staff braces for "substantial" layoffs
Pharmalot has been piecing together the likely fallout from Pfizer's move to restructure its R&D system. Sources are telling Pharmalot that layoffs will be "substantial," though there's no direct word on just what kind of numbers are to be expected.
Pfizer is eliminating heart disease, obesity and other research areas and is discussing spinning off some of the units--with employees. Meanwhile, employees in the R&D section are being scored; assigned a number based on "performance, skill and attitude."
The picture should clarify by the end of this year, though, when Pfizer plans to have the new R&D structure all set up and in operation. A spokesperson for Pfizer had nothing new to offer by way of explanation.
- check out the report from Pharmalot
Related Articles:
Pfizer, UCB, UK create tech company to speed R&D
Hinting at layoffs, Pfizer extends severance
Pfizer plans big push into generics
Pfizer unveils realignment of global ops
Report: Pfizer considering sale of research units
Comments
I have learned to that Pfizer will be laying off all 30,000 Contractors as of 12.31.08. All will be offered permanant positions at below market rate!
Just finished a con-call with Procurement and it is 100% true. It has not hit the wire yet !
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities

SHARE
WITH: